Close Window
Aetna Aetna
Clinical Policy Bulletin:
Color-Flow Doppler Echocardiography in Adults
Number: 0008


Policy

  1. Aetna considers color-flow Doppler echocardiography in adults medically necessary for the following indications:

    1. Evaluation of aortic diseases
    2. Evaluation of aortocoronary bypass grafts
    3. Evaluation of hypertrophic cardiomyopathy (formerly known as idiopathic hypertrophic subaortic stenosis)
    4. Evaluation of prosthetic valves
    5. Evaluation of septal defects
    6. Evaluation of site of left-to-right or right-to-left shunts
    7. Evaluation of the severity of valve stenosis and regurgitation
       
  2. Aetna considers color-flow Doppler echocardiography in adults experimental and investigational for all other indications (e.g., to guide catheter ablation in ventricular tachycardia) because its effectiveness for these indications has not been established.

See also CPB 0106 - Fetal Echocardiograms, and CPB 0382 - Intravascular Ultrasound.



Background

This policy is based on guidelines on diagnostic echocardiography in adults from the American College of Cardiology (Cheitlin et al, 2003).

Echocardiography is an ultrasound technique for diagnosing cardiovascular disorders.  It is subdivided into M-mode, two-dimensional (2-D), spectral Doppler, color Doppler, contrast, and stress echocardiography (Beers and Berkow, 1999).

Echocardiography is usually performed by placing a transducer over the chest.  In transesophageal echocardiography, however, the transducer is placed at the tip of an endoscope that is inserted into the esophagus (Beers and Berkow, 1999).  Even smaller transducers can be placed on intravascular catheters, permitting intravascular recordings of vessel anatomy and blood flow.

Two-dimensional (or cross-sectional) echocardiography is the dominant echocardiographic technique (Beers and Berkow, 1999; Gottdiener et al, 2004).  It uses pulsed, reflected ultrasound to provide spatially correct real time tomographic images of the heart, which are recorded on videotape and resemble cineangiograms.  Two-dimensional echocardiography provides information about the cardiac chamber size, wall thickness, global and regional systolic function, and valvular and vascular structures.  B-mode imaging refers to cross-sectional 2-D images displayed without motion, and provides detail of static structures.

M-mode (or motion-mode) echocardiography creates a continuous 1-D graphic display, and is useful for measuring single dimensions of walls and chambers of the heart, which can be used to estimate chamber volumes and left ventricular mass (Beers and Berkow, 1999; Gottdiener et al, 2004).  M-mode echocardiography is performed by directing a stationary pulsed ultrasound beam at some portion of the heart. 

The Doppler technique uses reflections from moving red blood cells to characterize blood flow (Beers and Berkow, 1999; Gottdiener et al, 2004).  Spectral Doppler echocardiography uses ultrasound to record the velocity, direction, and type of blood flow in the cardiovascular system.  The spectral Doppler signal is displayed on a strip chart recorder or videotape. 

Stress echocardiography uses any combination of the above echocardiography modalities, before and during (or shortly after) a physical or pharmacological stress intervention (Beers and Berkow, 1999; Gottdiener et al, 2004).  Most commonly, a treadmill or exercise bicycle is used for stress echocardiography.  In patients who are unable to exercise, stress testing can be performed with pharmacological agents, such as dobutamine, that increased myocardial oxygen demand, or vasodilators that produce coronary steal.  These tests have utility primarily in the detection of myocardial ischemia and viability. 

Contrast echocardiography is an M-mode or 2-D echocardiographic examination during which contrast agents are administered via venous injection (Beers and Berkow, 1999; Gottdiener et al, 2004).  Venous contrast injections are used to enhance left ventricular endocardial borders and Doppler signals and to assess myocardial perfusion.

Color Doppler echocardiography is essentially 2-D Doppler echocardiography with flow encoded in color to show its direction (red is toward and blue is away from the transducer) (Beers and Berkow, 1999; Gottdiener et al, 2004).  In color flow mapping, blood flow velocity is measured along each sector line of a 2-D echocardiographic image and is displayed as color coded pixels.  Color flow Doppler is most useful for assessing valves for regurgitation and stenosis, detecting the presence of intracardiac shunts, and imaging blood flow in the heart.

Evidence-based guidelines from the American College of Cardiology, American Heart Association, and American Society of Echocardiography (Antman et al, 2003) outlined the accepted capabilities for Doppler echocardiography in the adult patient.  Specific indications were classified as relating to "anatomy-pathology" or to "function", and each potential indication was rated from "most helpful" to "not useful."  

Among indications related to anatomy-pathology, color Doppler was rated as most helpful for evaluating septal defects (Antman et al, 2003).  Color Doppler was considered not useful for all other indications related to anatomy-pathology: evaluation of chamber size, thickness of walls, relation of chambers, early closure of mitral valve, systolic anterior motion of mitral valve, left ventricular mass, left ventricular masses (tumor, clot, vegetation), masses in atria and right ventricle, anatomic valvular pathology, and pericardial effusion. 

Among functional indications, color Doppler was considered most useful for evaluating the site of right-to-left and left-to-right shunts (Antman et al, 2003).  Color Doppler was also considered useful for evaluating severity of valve stenosis and valve regurgitation and evaluation of prosthetic valves.  Color Doppler was also considered to be of some use in evaluating aortic diseases.  Color Doppler was considered not useful for assessment of global left ventricular systolic function (ejection fraction), evaluation of regional wall motion, measurement of right ventricular and pulmonary artery systolic pressures, measurement of left ventricular filling pressure, measurement of stroke volume and cardiac output, assessment of left ventricular diastolic function, and identifying ischemia and viable myocardium with exercise or pharmacological stress.

Nishimura et al (2011) examined the significance of measurement of stenosis by aliasing coronary flow (the MOSAIC method) for the detection of proximal left coronary stenosis in patients with unstable angina (UA) by means of transthoracic Doppler echocardiography.  Patients (n = 107) with UA were evaluated.  Proximal left coronary flow was sought in the short axis at the aortic root level using color Doppler guidance.  When detected coronary flow showed color aliasing, the color velocity range was gradually increased until color aliasing nearly disappeared.  Then, the color baseline was shifted until the color flow showed "isovelocity".  Proximal coronary flow was detected in 86 (80.4 %) of 107 patients.  In these 86 patients, an optimal cut-off value of isovelocity greater than or equal to 47.5 cm/second predicted significant coronary stenosis (percent diameter stenosis greater than or equal to 70 %) of the proximal left anterior descending (American Heart Association segment 6) or left main coronary artery with a sensitivity of 88 %, specificity of 97 %, positive predictive value of 98 %, and negative predictive value of 86 %.  In all 107 patients, the same cut-off value predicted significant coronary stenosis with a sensitivity of 78 %, specificity of 98 %, positive predictive value of 98 %, and negative predictive value of 81 %.  The authors concluded that the MOSAIC method may play a complementary role in expeditious risk stratification and decision making in patients with UA.

The American College of Radiology's Expert Panel on Cardiovascular Imaging (Ho et al, 2011) states that echocardiography using color flow Doppler is essential for evaluating blood flow as seen across an atrial defect or a ventricular septal defect or across a valve.  Assessment of the valves (sclerosis, fusion, estimation of valve gradients) and determination of right ventricular systolic pressure can usually be achieved.

An UpToDate review on "Catheter ablation for ventricular arrhythmias" (Ganz, 2012) states that "[i]ntracardiac echocardiography (ICE) with 2D and Doppler color flow imaging may be useful to guide mapping and ablation catheters and monitor morphologic changes after ablation".  The reference cited was the study by Ren et al (2002) that comprised only 4 patients with ventricular tachycardia.  Thus, there is currently insufficient evidence to support the use of color-flow Doppler echocardiography during ventricular tachycardia ablation.

An UpToDate review on “Principles of Doppler echocardiography” (Manning, 2013) states that “Color flow imaging is typically used in the screening and assessment of regurgitant flows.  It is also useful in the assessment of intracardiac shunts (e.g., atrial and ventricular septal defects) and pulmonary vein flow, and to assist in continuous wave Doppler alignment for tricuspid regurgitation velocities”.

Appendix

Note on documentation requirements: Physicians are reminded to bill the findings of the diagnostic test as the primary indication rather than the referring physician’s diagnosis, as indicated by Medicare’s Diagnostic Imaging Billing guidelines.  These guidelines are available at the following website: http://www.cms.hhs.gov/manuals/downloads/clm104c23.pdf.  This is also indicated in the ICD-9-CM Coding Guidelines, Section IV, Paragraph L. 

 
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
+ 93325
Other CPT codes related to the CPB [parent codes for 93325]:
76825
76826
76827
76828
93303
93304
93308
93312
93314
93315
93317
+ 93320
+ 93321
93350
93351
93650
93653
93654
Other HCPCS related to the CPB:
C1886 Catheter, extravascular tissue ablation, any modality (insertable) [experimental and investigational to guide catheter ablation procedures in ventricular tachycardia]
ICD-9 codes covered if selection criteria are met:
038.0 Streptococcal septicemia
038.10 - 038.19 Staphylococcal septicemia
038.2 Pneumococcal septicemia [Streptococcus pneumoniae septicemia]
038.3 Septicemia due to anaerobes
038.40 Gram-negative organism, unspecified
038.41 Septicemia due to Hemophilus influenzae [H. influenzae]
038.42 Septicemia due to Escherichia coli [E. coli]
038.43 Septicemia due to Pseudomonas
038.44 Septicemia due to Serratia
093.20 - 093.24 Syphilitic endocarditis
098.84 Gonococcal endocarditis
115.03 Infection by Histoplasma capsulatum, pericarditis
115.04 Infection by Histoplasma capsulatum, endocarditis
391.1 Acute rheumatic endocarditis
391.2 Acute rheumatic myocarditis
391.8 Other acute rheumatic heart disease
391.9 Acute rheumatic heart disease, unspecified
392.0 Rheumatic chorea with heart involvement
394.0 - 394.9 Diseases of mitral valve
395.0 - 395.9 Diseases of aortic valve
396.0 - 396.9 Diseases of mitral and aortic valves
397.0 Diseases of tricuspid valve
397.1 Rheumatic diseases of pulmonary valve
398.0 - 398.99 Other rheumatic heart disease
410.00 - 410.91 Acute myocardial infarction
414.10 - 414.19 Aneurysm of heart
415.0 Acute cor pulmonale
421.0 - 421.9 Acute and subacute endocarditis
422.0 - 422.99 Acute myocarditis
424.0 - 424.99 Other diseases of endocardium
425.0 - 425.9 Cardiomyopathy
427.31 - 427.32 Atrial fibrillation and flutter
428.0 - 428.9 Heart failure, unspecified
429.0 Myocarditis, unspecified
429.3 Cardiomegaly
429.5 Rupture of chordae tendineae
429.6 Rupture of papillary muscle
429.71 Acquired cardiac septal defect
429.81 Other disorders of papillary muscle
429.83 Takotsubo syndrome
441.00 - 441.9 Aortic aneurysm and dissection
446.7 Takayasu's disease
458.0 - 458.9 Hypotension, unspecified
518.4 Acute edema of lung, unspecified
647.63 Other viral diseases complicating pregnancy, antepartum condition or complication
647.83 Other specified infectious and parasitic diseases complicating pregnancy, antepartum condition or complication
647.93 Unspecified infectious and parasitic diseases complicating pregnancy, antepartum condition or complication
648.03 Diabetes mellitus complicating pregnancy, antepartum condition or complication
648.50 - 648.54 Congenital cardiovascular disorders in the mother complicating pregnancy, antepartum condition or complication
648.60 - 648.64 Other cardiovascular diseases in the mother complicating pregnancy
653.63 Hydrocephalic fetus causing disproportion, antepartum condition or complication
655.03 Central nervous system malformation in fetus affecting management of mother, antepartum condition or complication
655.13 Known or suspected chromosomal abnormality in fetus affecting management of mother, antepartum condition or complication
655.23 Hereditary disease in family possibly affecting fetus affecting management of mother, antepartum condition or complication
655.33 Suspected damage to fetus from viral disease in mother, antepartum condition or complication
655.43 Suspected damage to fetus from other disease affecting management of mother, antepartum condition or complication
655.53 Suspected damage to fetus from drugs affecting management of mother, antepartum condition or complication
655.83 Other known or suspected fetal abnormality affecting management of the mother, not elsewhere classified
655.93 Unspecified known or suspected fetal abnormality, not elsewhere classified, affecting management of mother, antepartum condition or complication
656.03 Fetal-maternal hemorrhage affecting management of mother, antepartum condition or complication
656.13 Rhesus isoimmunization affecting management of mother, antepartum condition or complication
656.23 Isoimmunization from other and unspecified blood-group incompatibility affecting management of mother, antepartum condition or complication
657.03 Polyhydramnios, antepartum condition or complication
659.73 Abnormality in fetal heart rate or rhythm, antepartum condition or complication
745.0 - 745.9 Bulbus cordis anomalies and anomalies of cardiac septal closure
746.00 - 746.09 Anomalies of pulmonary valve
746.1 Tricuspid atresia and stenosis, congenital
746.2 Ebstein's anomaly
746.3 Congenital stenosis of aortic valve
746.4 Congenital insufficiency of aortic valve
746.5 Congenital mitral stenosis
746.6 Congenital mitral insufficiency
746.7 Hypoplastic left heart syndrome
746.81 Subaortic stenosis
746.82 Cor triatriatum
746.83 Infundibular pulmonic stenosis
746.84 Obstructive anomalies of heart, not elsewhere classified
747.0 - 747.49 Anomalies of great veins
747.83 Persistent fetal circulation
759.82 Marfan syndrome
760.71 Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol
760.77 Noxious influences affecting fetus or newborn via placenta or breast milk, anticonvulsants
762.3 Fetus or newborn affected by placental transfusion syndromes
763.81 Abnormality in fetal heart rate or rhythm before the onset of labor, affecting fetus or newborn
763.83 Abnormality in fetal heart rate or rhythm, unspecified as to time of onset, affecting fetus or newborn
775.0 Syndrome of "infant of a diabetic mother", fetus or newborn
778.0 Hydrops fetalis not due to isoimmunization, fetus or newborn
785.2 Undiagnosed cardiac murmurs
996.02 Mechanical complication due to heart valve prosthesis
996.03 Mechanical complication due to coronary bypass graft
996.61 Infection and inflammatory reaction due to cardiac device, implant, and graft
996.71 Other complications due to heart valve prosthesis
996.83 Complications of transplanted heart
V13.65 Personal history of congenital malformations of heart and circulatory system
V42.2 Organ or tissue replaced by transplant, heart valve
V43.3 Organ or tissue replaced by other means, heart valve
V45.81 Aortocoronary bypass status
ICD-9 codes not covered for indications listed in the CPB: :
427.1 Paroxysmal ventricular tachycardia [not covered to guide catheter ablation]


The above policy is based on the following references:
  1. Antman EM, Smith SC, Alpert JS, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography. ACC/AHA Practice Guidelines. Dallas, TX: American Heart Association; 2003. Available at: http://www.americanheart.org/. Accessed March 5, 2005.
  2. Gottdiener JS, Bednarz J, Devereix R, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Echocardiography in Clinical Trials. American Society of Echocardiography Report. J Am Soc Echocardiography. 2004;17(10):1086-1119.
  3. Beers MH, Berkow R, eds. Diagnostic cardiovascular procedures. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co.; 1999.
  4. Pinheiro AC, Mancuso FJ, Hemerly DF, et al. Diagnostic value of color flow mapping and Doppler echocardiography in the quantification of mitral regurgitation in patients with mitral valve prolapse or rheumatic heart disease. J Am Soc Echocardiogr. 2007;20(10):1141-1148.
  5. Nishimura K, Okayama H, Inoue K, et al. Usefulness of the MOSAIC (measurement of stenosis by aliasing coronary flow) method using transthoracic color Doppler echocardiography in unstable angina patients. Int J Cardiol. 2011;151(2):170-174.
  6. Ho VB, Biko DM, White RD, et al, Expert Panel on Cardiovascular Imaging. Known or suspected congenital heart disease in the adult. ACR Appropriateness Criteria [online publication]. Reston, VA: American College of Radiology (ACR); 2011.
  7. Ren JF, Marchlinski FE, Callans DJ, Herrmann HC. Clinical use of AcuNav diagnostic ultrasound catheter imaging during left heart radiofrequency ablation and transcatheter closure procedures. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1301-1308.
  8. Ganz LI. Catheter ablation for ventricular arrhythmias. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed September 2012.
  9. Manning WJ. Principles of Doppler echocardiography. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed September 2013.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top